An efficient approach to expand equitable access to antiobesity medications: deprescribing after weight loss plateau
Open accessAbstract
The authors advocate for a consideration of 2 distinct phases of obesity management (ie, active weight loss and maintenance of weight loss) to allow substantially more people access to antiobesity medications.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
This approach (duration limits) has been suggested by academics in the US and has been implemented by the NHS in England.
“this approach has been suggested by academics in the US and has been implemented by the NHS in England [63,72].”
From Affordable access to GLP-1 obesity medications: strategies to guide market action and policy solutions in the US (2025) · cites this paper as [72]
In the main text (page unavailable), the US-based authors propose moving patients from full-dose antiobesity medication to a lower-cost maintenance program after a weight-loss plateau. That partly supports the claim that US academics suggested limiting treatment duration, but their proposal is tied to a clinical plateau rather than a fixed duration limit. The paper does not say that the NHS implemented duration limits in England. (LLM, conf=0.84)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 1 · Cited by 1
- Authors
- Kim, D. D., & Fendrick, A. M.
- Affiliations
- University of Chicago (US)
- Venue
- The American Journal of Managed Care
- Published
- 2024-07-29
- Volume
- 30
- Issue
- 8
- Pages
- 348-350
- ISSN
- 1088-0224 (ISSN-L)
- 1936-2692
- PMC
- PMC12171982
- OpenAlex
- W4401597015
- Cited by
- 1
- References
- 1
- Citations by year
- 2025: 1
- FWCI
- 0.28
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The American Journal of Managed Care (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Department of Defense
- American Heart Association
- Yale University
- National Pharmaceutical Council
- Arnold Ventures
- Yale New Haven Hospital
- National Institutes of Health
- National Heart, Lung, and Blood Institute
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK092949)
- National Institute on Minority Health and Health Disparities
- Topics
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Health Sciences › Health Professions › Pharmacy › Obesity and Health Practices
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Keywords
- anti-obesity drugs, deprescribing, weight loss plateau, obesity treatment, weight loss maintenance
- MeSH terms
- Deprescriptions, Health Services Accessibility, Humans, Obesity, United States, Weight Loss, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
